- Conditions
- HIV-1
- Interventions
- D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV
- Interventions
- Biktarvy
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- HIV-1-Infection
- Interventions
- ISL/LEN, Antiretroviral Combinations
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida
- Conditions
- HIV/AIDS, PrEP
- Interventions
- PrEP screening program, PrEP starter pack
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV I Infection
- Interventions
- Estradiol
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more
- Conditions
- HIV-1 Infection
- Interventions
- Lenacapavir, Placebo, B/F/TAF, TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Sacramento, California • Torrance, California + 7 more
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
- Interventions
- ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 4 Weeks to 17 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 7
- States / cities
- Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
- Conditions
- HIV Infections
- Interventions
- Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Timeline
- 2026 – 2029
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- Up to 120 Hours
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Atlanta, Georgia • Memphis, Tennessee
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
- Drug
- Lead sponsor
- Quest Clinical Research
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Human Immunodeficiency Virus Type 1
- Interventions
- D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
- Conditions
- HIV-1/HBV Co-Infection
- Interventions
- B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more
- Conditions
- HIV Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
- Conditions
- HIV-1 Infection
- Interventions
- elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
- Conditions
- Healthy Volunteer, HIV Prevention
- Interventions
- tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
- Interventions
- Doravirine 100 Mg
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- HIV Infections
- Interventions
- GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more
- Conditions
- HIV Infections, Substance Use, Adherence, Medication, Adherence, Treatment
- Interventions
- Descovy or Truvada, ID-Cap System, Beiwe
- Drug · Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
- Conditions
- HIV Infections
- Interventions
- B/FTC/TAF, Current ART
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV-1-infection
- Interventions
- Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, SBR
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Berkeley, Michigan • Annandale, Virginia